Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer
- PMID: 23536561
- PMCID: PMC3688270
- DOI: 10.1158/0008-5472.CAN-12-2388
Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer
Abstract
Bladder cancer results from the combined effects of environmental and genetic factors, smoking being the strongest risk factor. Evaluating absolute risks resulting from the joint effects of smoking and genetic factors is critical to assess the public health relevance of genetic information. Analyses included up to 3,942 cases and 5,680 controls of European background in seven studies. We tested for multiplicative and additive interactions between smoking and 12 susceptibility loci, individually and combined as a polygenic risk score (PRS). Thirty-year absolute risks and risk differences by levels of the PRS were estimated for U.S. males aged 50 years. Six of 12 variants showed significant additive gene-environment interactions, most notably NAT2 (P = 7 × 10(-4)) and UGT1A6 (P = 8 × 10(-4)). The 30-year absolute risk of bladder cancer in U.S. males was 6.2% for all current smokers. This risk ranged from 2.9% for current smokers in the lowest quartile of the PRS to 9.9% for current smokers in the upper quartile. Risk difference estimates indicated that 8,200 cases would be prevented if elimination of smoking occurred in 100,000 men in the upper PRS quartile compared with 2,000 cases prevented by a similar effort in the lowest PRS quartile (P(additive) = 1 × 10(-4)). Thus, the potential impact of eliminating smoking on the number of bladder cancer cases prevented is larger for individuals at higher than lower genetic risk. Our findings could have implications for targeted prevention strategies. However, other smoking-related diseases, as well as practical and ethical considerations, need to be considered before any recommendations could be made.
©2012 AACR.
Figures
Comment in
-
Bladder cancer: Towards risk stratification in bladder cancer.Nat Rev Urol. 2013 Jul;10(7):374-5. doi: 10.1038/nrurol.2013.114. Epub 2013 May 21. Nat Rev Urol. 2013. PMID: 23689256 No abstract available.
-
Commentary on "common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer." Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, Jacobs EJ, Malats N, De Vivo I, Albanes D, Purdue MP, Sharma S, Fu YP, Kogevinas M, Wang Z, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr., Grubb R 3rd, Black A, Gapstur SM, Thun M, Diver WR, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT, Hutchinson A, Burdett L, Jacobs KB, Yeager M, Fraumeni JF Jr., Chanock SJ, Silverman DT, Chatterjee N, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.: Cancer Res 2013;73(7):2211-20 [Epub 2013 Mar 27].Urol Oncol. 2014 Feb;32(2):213-4. doi: 10.1016/j.urolonc.2013.08.015. Urol Oncol. 2014. PMID: 24445297
References
-
- Silverman D, SS D, LE M, N R. Bladder Cancer. Cancer Epidemiology and Prevention. 2006:1101–1127.
-
- Amling CL. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer. 2001;25:219–278. - PubMed
Publication types
MeSH terms
Grants and funding
- U01 HG004446/HG/NHGRI NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- HHSN261201000006C/CP/NCI NIH HHS/United States
- R01 CA089715/CA/NCI NIH HHS/United States
- R01- CA34627/CA/NCI NIH HHS/United States
- Y99 CA999999/CA/NCI NIH HHS/United States
- HHSN268200782096C/HG/NHGRI NIH HHS/United States
- R01HL091172-01/HL/NHLBI NIH HHS/United States
- R01 CA034627/CA/NCI NIH HHS/United States
- Z99 CA999999/ImNIH/Intramural NIH HHS/United States
- CA055075/CA/NCI NIH HHS/United States
- HHSN261200800001E/CA/NCI NIH HHS/United States
- R01 CA057494/CA/NCI NIH HHS/United States
- U01HG004438/HG/NHGRI NIH HHS/United States
- N01-RC-45035/RC/CCR NIH HHS/United States
- U01 HG004438/HG/NHGRI NIH HHS/United States
- N02 CP001037/CP/NCI NIH HHS/United States
- N02 CP011015/CP/NCI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- CA087969/CA/NCI NIH HHS/United States
- HG-06-033/HG/NHGRI NIH HHS/United States
- N01 RC037004/RC/CCR NIH HHS/United States
- N02-CP-01037/CP/NCI NIH HHS/United States
- R01- CA089715/CA/NCI NIH HHS/United States
- N01 CN045165/CN/NCI NIH HHS/United States
- HHSN261200800001C/RC/CCR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources